全文获取类型
收费全文 | 4233篇 |
免费 | 307篇 |
国内免费 | 301篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 42篇 |
妇产科学 | 18篇 |
基础医学 | 188篇 |
口腔科学 | 35篇 |
临床医学 | 596篇 |
内科学 | 1725篇 |
皮肤病学 | 5篇 |
神经病学 | 61篇 |
特种医学 | 151篇 |
外科学 | 592篇 |
综合类 | 778篇 |
预防医学 | 111篇 |
眼科学 | 30篇 |
药学 | 376篇 |
20篇 | |
中国医学 | 60篇 |
肿瘤学 | 28篇 |
出版年
2024年 | 2篇 |
2023年 | 95篇 |
2022年 | 132篇 |
2021年 | 234篇 |
2020年 | 271篇 |
2019年 | 175篇 |
2018年 | 118篇 |
2017年 | 95篇 |
2016年 | 143篇 |
2015年 | 184篇 |
2014年 | 480篇 |
2013年 | 389篇 |
2012年 | 520篇 |
2011年 | 406篇 |
2010年 | 379篇 |
2009年 | 254篇 |
2008年 | 165篇 |
2007年 | 191篇 |
2006年 | 154篇 |
2005年 | 102篇 |
2004年 | 68篇 |
2003年 | 58篇 |
2002年 | 70篇 |
2001年 | 46篇 |
2000年 | 20篇 |
1999年 | 28篇 |
1998年 | 18篇 |
1997年 | 15篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1989年 | 3篇 |
1988年 | 2篇 |
排序方式: 共有4841条查询结果,搜索用时 15 毫秒
101.
目的建立HPLC-MS/MS法测定丹参素钠、原儿茶醛、咖啡酸、迷迭香酸和丹酚酸A在大鼠血浆中浓度的方法。方法用乙腈蛋白沉淀法处理血浆样本,色谱柱为Synergi Hydro-RP 80 A(150 mm×2 mm,4μm),流动相为乙腈-0.1%甲酸水溶液,梯度洗脱,0~2 min,10%~60%乙腈;2~3 min,60%~95%乙腈;3~6.5 min,95%乙腈;6.5~7 min,95%~10%乙腈;7~12 min,10%乙腈,流速为0.4 m L·min-1;电喷雾电离(ESI)离子源离子化,采用多重反应监测(MRM)方式进行负离子检测。结果丹参素钠、原儿茶醛、咖啡酸、迷迭香酸和丹酚酸A的线性范围分别为10~1000,5~500,2~200,5~500,10~1000ng·m L-1;定量下限分别为10,5,2,5,10 ng·m L-1。日内精密度(RSD)均小于8.31%,日间RSD均小于12.73%,提取回收率均大于50%。结论本检测方法专属性高,操作简便,稳定性好,可以同时准确地检测丹参素钠、原儿茶醛、咖啡酸、迷迭香酸和丹酚酸A的血药浓度。 相似文献
102.
目的:探讨血液细胞成分与男性冠状动脉慢血流( SCF)的关系。方法2011年8月至2012年8月经造影证实冠状动脉狭窄<40%的男性患者199例,根据校正的TIMI血流计帧法分为SCF组151例,正常对照组48例,比较2组临床变量。结果2组高血压病、2型糖尿病、吸烟史和冠脉轻度狭窄比例差异无统计学意义(P >0?.05)。 SCF组年龄较低,而高脂血症比例高于正常对照组( P <0.05)。血液细胞成分比较发现SCF组白细胞计数[6.70(5.62,7.94),6.12(5.38,6.65)]、血红蛋白[150(142,157),145(137,151)]和红细胞压积[43.2(40.74,5.0),42.2(40.4,44.2)]高于正常对照组( P <0.05),多因素分析提示高脂血症( P =0.014,OR 2.385,95%CI 1.197~4.753)和血红蛋白( P =0.030,OR 1.034,95%CI 1.003~1.066)是SCF的独立影响因素。结论高脂血症和血红蛋白是男性冠状动脉SCF的临床影响因素。 相似文献
103.
104.
Motasem Alyamani Sandra Campbell Eliano Navarese Robert C. Welsh Kevin R. Bainey 《The Canadian journal of cardiology》2021,37(2):339-346
BackgroundPrimary percutaneous coronary intervention (PPCI) is the preferred method of reperfusion in ST-elevation myocardial infarction. However, microvascular perfusion is often impaired due to distal embolization of thrombus. Intracoronary (IC) thrombolysis may attenuate thrombotic burden. We conducted a meta-analysis comparing the benefits and risks of IC thrombolytic therapy as an adjunct to PPCI.MethodsRandomized controlled trials (RCTs) were identified through search of Medline, EMBASE, Scopus, Web of Science, Cochrane Library (Cochrane Reviews and Cochrane Protocols), PROSPERO, and clinicaltrials.gov from 1946 to January 2019. Studies included patients with ST-elevation myocardial infarction undergoing primary PCI receiving IC thrombolytic agents. Both safety and efficacy outcomes were explored. Data were combined using a fixed-effects model.ResultsOf 1278 citations identified, 6 RCTs (890 patients; 519 IC thrombolytic and 371 IC placebo) were included. Post-PCI thrombolysis in myocardial infarction (TIMI) flow grade 2/3 occurred in 97.1% of the IC thrombolytic group vs 95.1% of the IC placebo group (odds ratio [OR], 0.57; 95% confidence interval [CI], 0.28-1.17; P = 0.13). Complete ST-segment resolution was more common with IC thrombolysis (OR, 0.29; 95% CI, 0.15-0.57; P = 0.0003). There was a strong trend favouring fewer in-hospital major adverse cardiac events with IC thrombolysis when compared with IC placebo (OR, 0.64; 95% CI, 0.41-1.01; P = 0.05). There was no difference in bleeding (TIMI major, TIMI minor, and Bleeding Academic Research Consortium [BARC] 3-5 bleeds) between the 2 groups (OR, 1.36; 95% CI, 0.38-3.54; P = 4.84).ConclusionsGiven the limited studies to date, our meta-analysis suggests that a targeted IC thrombolytic approach is safe and potentially effective to augment PPCI. However, these findings deserve confirmation in a larger RCT. 相似文献
105.
Zhu Yong Meng Shuai Chen Maolin Jia Ruofei Nan Jing Li Hong Zhu Huagang Li Long Jin Zening 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2021,35(5):995-1002
Cardiovascular Drugs and Therapy - This meta-analysis compared the efficacy and safety of oral anticoagulation (OAC) therapy alone versus OAC plus single antiplatelet therapy (SAPT) in patients... 相似文献
106.
Clinical Rheumatology - Takayasu’s arteritis (TA) may involve the pulmonary artery, which signifies a poor prognosis. This study investigated the features of TA patients with pulmonary artery... 相似文献
107.
Zhen Huang Pan Huang Binbin Du Lingyao Kong Wenyuan Zhang Yanzhou Zhang Jianzeng Dong 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(1):2-13
Background and aimsEmerging data have linked the presence of cardiac injury with a worse prognosis in novel coronavirus disease 2019 (COVID-19) patients. However, available data cannot clearly characterize the correlation between cardiac injury and COVID-19. Thus, we conducted a meta-analysis of recent studies to 1) explore the prevalence of cardiac injury in different types of COVID-19 patients and 2) evaluate the association between cardiac injury and worse prognosis (severe disease, admission to ICU, and mortality) in patients with COVID-19.Methods and resultsLiterature search was conducted through PubMed, the Cochrane Library, Embase, and MedRxiv databases. A meta-analysis was performed with Stata 14.0. A fixed-effects model was used if the I2 values ≤ 50%, otherwise the random-effects model was performed. The prevalence of cardiac injury was 19% (95% CI: 0.15–0.22, and p < 0.001) in total COVID-19 patients, 36% (95% CI: 0.25–0.47, and p < 0.001) in severe COVID-19 patients, and 48% (95% CI: 0.30–0.66, and p < 0.001) in non-survivors. Furthermore, cardiac injury was found to be associated with a significant increase in the risk of poor outcomes with a pooled effect size (ES) of 8.46 (95% CI: 3.76–19.06, and p = 0.062), severe disease with an ES of 3.54 (95% CI: 2.25–5.58, and p < 0.001), admission to ICU with an ES of 5.03 (95% CI: 2.69–9.39, and p < 0.001), and mortality with an ES of 4.99 (95% CI: 3.38–7.37, and p < 0.001).ConclusionsThe prevalence of cardiac injury was greatly increased in COVID-19 patients, particularly in patients with severe disease and non-survivors. COVID-19 patients with cardiac injury are more likely to be associated with poor outcomes, severity of disease, admission to ICU, and mortality. 相似文献
108.
目的:探讨新型口服抗凝药(NOAC)用于心力衰竭合并左心室血栓患者的疗效。方法:入选2017年1月至2020年6月在首都医科大学附属北京安贞医院心力衰竭中心门诊和住院患者中明确诊断为心力衰竭合并左心室血栓患者100例,分别给予NOAC(NOAC组,42例)或维生素K受体拮抗剂(VKA组,58例)治疗,3个月后复查经胸超声心动图。结果:两组患者在年龄、性别、心血管危险因素和基础疾病、左心室射血分数等方面的差异均无统计学意义(P均>0.05)。在NOAC组,利伐沙班治疗者30例,达比加群治疗者12例,3个月时血栓完全溶解率为69.0%。所有VKA组患者均使用华法林治疗,血栓完全溶解率为63.8%,与NOAC组相比差异无统计学意义(P>0.05)。3个月期间,两组均未发生栓塞事件和致死性大出血事件,仅VKA组有2例胃肠道出血,对症治疗后即好转。结论:NOAC可考虑作为心力衰竭合并左心室血栓患者的治疗药物。 相似文献
109.
目的探索影响慢性完全闭塞(CTO)病变行经皮冠状动脉介入治疗(PCI)结局的患者临床特点与冠状动脉造影(CAG)图像特征,对比日本多中心CTO注册中心(J-CTO)评分、临床-病变相关(CL)评分对PCI结局的预测价值。方法纳入2019年1月1日至2019年6月30日于首都医科大学附属北京安贞医院行CAG检查确诊CTO病变并尝试进行PCI的157例患者共162处病变。根据病变行PCI是否全部成功分为PCI成功患者组(121例)以及PCI失败患者组(36例),根据病变最终是否成功开通分为PCI成功组(125处)以及PCI失败组(37处)。收集患者临床及CAG病变特征资料,分析影响CTO-PCI成功的因素,采用CL评分及J-CTO评分分别对病变进行评价,比较预测价值差异。结果157例患者中男性130例(82.8%),平均年龄(60.0±9.7)岁,最终PCI成功开通CTO病变125处(77.2%)。PCI失败患者组既往CTO病变PCI失败(33.3%比16.5%,P=0.028)、既往PCI(47.2%比28.1%,P=0.035)比例显著大于PCI成功患者组,差异均有统计学意义。PCI失败组近端钝形纤维帽(56.8%比32.0%,P=0.006)、病变长度≥20 mm(67.6%比22.4%,P<0.001)、病变迂曲>45°(45.9%比16.0%,P<0.001)以及侧支循环Rentrop 0~1级比例(27.0%比9.6%,P=0.007),J-CTO评分[(2.24±1.01)分比(1.05±0.94)分,P<0.001]、CL评分[(3.01±1.22)分比(1.80±1.26)分,P<0.001]均高于PCI成功组,差异均有统计学意义。logistic多因素回归分析显示,病变长度≥20 mm(OR 0.216,95%CI 0.082~0.569,P=0.002)、近端钝形纤维帽(OR 0.232,95%CI 0.091~0.590,P=0.002)以及侧支循环Rentrop 0~1级(OR 0.299,95%CI 0.094~0.949,P=0.040)为PCI成功开通CTO病变的独立危险因素。CL评分及J-CTO评分预测PCI结局的受试者工作特征曲线下面积分别为0.749(95%CI 0.675~0.814)和0.794(95%CI 0.723~0.853),两者比较差异无统计学意义(P=0.260)。结论病变长度≥20 mm、近端钝形纤维帽以及侧支循环Rentrop 0~1级为PCI成功开通CTO病变的独立危险因素。在预测CTO-PCI结局方面,CL评分与J-CTO评分预测价值相当。 相似文献
110.